Alisertib will be assessed in patients with small cell lung cancer as part of the phase 2 Study PUMA-ALI-4201.

Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Investigators of a phase 1a trial report high objective response rates in patients receiving forimtamig for relapsed/refractory multiple myeloma, including those with high-risk cytogenetics and extra medullary disease.

Most adverse effects appear to be grade 1 or 2 among patients with hepatocellular carcinoma and other solid tumors associated with the MYC oncogene receiving OTX-2002 in the phase 1/2 MYCHELANGELO I trial.

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.

Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.

The biologic license application for odronextamab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma is based on data from the phase 1 ELM- 1 and phase 2 ELM-2 studies.

Neeraj Agarwal, MD, states that he is optimistic about the development of new treatment options including immunotherapies, CAR T-cell therapies, and antibody-drug conjugates for metastatic prostate cancer.

Treatment with BI 764532 produces a manageable safety profile among those with small cell lung cancer and neuroendocrine carcinoma in a phase 1 trial.

APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.

When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.

Many patients with relapsed/refractory multiple myeloma appear to remain on treatment with mezigdomide-based regimens for more than 1 year, according to Albert Oriol, PhD.

Durcabtagene autoleucel shows robust expansion in vivo followed by persistence in approximately half of patients with relapsed/refractory multiple myeloma enrolled on a phase 1 trial.

Talquetamab appears to produce the highest overall response rates vs other types of bispecific antibody monotherapy among patients with relapsed/refractory multiple myeloma in a systematic review.

Investigators report no grade 3 or higher adverse effects in patients with multiple myeloma assigned to undergo strength building or walking as part of a study.

Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.

IDE161 is now eligible for inclusion in a development program allowing for expediated regulatory review following its FDA fast track designation status for advanced BRCA1/2-mutant ovarian cancer.

The safety and tolerability of IDE161 is being assessed as part of a phase 1 trial in solid malignancies including breast cancer.

Findings from the phase 2 GMMG-CONCEPT trial suggest that elevated lactate dehydrogenase levels correlated with worse survival in patients with newly diagnosed, high-risk multiple myeloma.

Lucio N. Gordan, MD, reviews how the chemotherapy drug shortages have led to price gouging, potentially making treatment unavailable to patients.

MYTX-011 is being assessed as part of the phase 1 KisMET-01 study in patients with locally advanced, recurrent or metastatic non–small cell lung cancer.

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.